Cargando…
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do...
Autores principales: | Turnbull, Samantha, West, Emma J., Scott, Karen J., Appleton, Elizabeth, Melcher, Alan, Ralph, Christy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690862/ https://www.ncbi.nlm.nih.gov/pubmed/26633468 http://dx.doi.org/10.3390/v7122938 |
Ejemplares similares
-
OBHDP Editorial: Where we are, how we got here, and where we’re going
por: Kouchaki, Maryam
Publicado: (2020) -
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2022) -
Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
por: van Westrhenen, Roos, et al.
Publicado: (2020) -
Diagnosing acute compartment syndrome—where have we got to?
por: McMillan, Tristan E., et al.
Publicado: (2019) -
Craniofacial genetics: Where have we been and where are we going?
por: Weinberg, Seth M., et al.
Publicado: (2018)